Details for Patent: 8,663,680
Summary for Patent: 8,663,680
| Title: | Transparent transdermal nicotine delivery devices | |||||||||||||||||||||||||||||||||||||||
| Abstract: | A transparent transdermal delivery device for delivering nicotine which has an Opacity Index of less than 48.6%. | |||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Robert M. Gale | |||||||||||||||||||||||||||||||||||||||
| Assignee: | Alza Corp | |||||||||||||||||||||||||||||||||||||||
| Application Number: | US13/311,437 | |||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Compound; Delivery; Device; | |||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 8,663,680: Scope, Claim Construction, Patent Landscape, and Generic Entry RiskU.S. Patent No. 8,663,680 protects a transparent nicotine transdermal patch defined primarily by its backing layer, low nicotine permeability, low nicotine solubility, optical transparency, and 18-to-24-hour delivery period. The independent claim is narrow in material selection but broad in product configuration. It does not claim nicotine as a chemical entity, a particular dose, a specific adhesive chemistry, or a manufacturing process. The patent was granted on March 4, 2014. The supplied claims establish the technical scope, but they do not establish the patent’s assignee, priority chain, terminal disclaimer, patent term adjustment, Orange Book status, or litigation history. Those legal and commercial issues cannot be determined from the claims alone. What does U.S. Patent 8,663,680 protect?The patent protects a nicotine transdermal administration device having four required elements:
Claim 1 is the controlling independent claim. Claims 2 through 9 add performance limitations involving nicotine permeability, nicotine solubility, opacity, and delivery duration. The patent is therefore directed to a patch architecture rather than to nicotine itself. A competing product that uses the same nicotine active ingredient but a different backing construction may avoid the literal scope of claim 1 if it does not satisfy the listed backing-material limitation. What backing materials are covered by claim 1?Claim 1 covers three expressly defined backing categories:
The third category is narrower than a generic “acrylonitrile copolymer” limitation. A film outside the stated monomer ranges or outside the specified graft-copolymer structure could present a non-infringement position, subject to claim construction and equivalents analysis. The claim does not require all three backing materials. A device using any one of the listed material categories may satisfy the backing limitation if the other elements are present. How should the independent claim be construed?“A backing layer formed from a material selected from the group”The “selected from the group consisting of” language ordinarily operates as a closed Markush group. The claim identifies three permitted backing-material classes. A backing formed from a materially different polymer system would not ordinarily satisfy this limitation literally. A multilayer structure may still qualify if the claimed material forms the backing layer or is incorporated into the backing construction. The outcome would depend on whether the accused product uses the claimed material as the backing layer rather than merely as an incidental packaging, release, or adhesive component. “A drug reservoir layer containing nicotine”The claim requires a reservoir layer. A matrix patch in which nicotine is dispersed through a polymer matrix may raise a claim-construction issue over a distinct reservoir layer. The claim does not specify nicotine concentration, salt form, solvent, rate-controlling membrane, or whether the reservoir is a liquid, gel, polymer matrix, or other composition. “An adhesive for maintaining the device in nicotine transmitting relationship with the skin”The adhesive must maintain skin contact and permit nicotine transmission. The claim does not require the adhesive to contain nicotine. A peripheral adhesive, an adhesive layer over the reservoir, or an adhesive-containing matrix could potentially qualify depending on the construction of the device. “Sufficiently transparent”The transparency limitation is functional. The patch must permit the user’s skin to be visible through the device. The claim does not specify a single transmittance threshold. Claims 6 through 8 introduce an Opacity Index limitation, but claim 1 itself does not recite a numerical opacity value. This creates a potential dispute over whether transparency is assessed by visual inspection, an objective optical measurement, or the quantitative test described in the patent specification. What additional limitations do claims 2 through 9 impose?The dependent claims create a performance-based hierarchy.
Claims 4 and 5 depend indirectly on the permeability limitations. Claim 5 therefore requires the claim 3 permeability threshold and the tighter solubility threshold. Claims 6 through 8 depend on claim 4, so they require the less restrictive permeability limitation of claim 2 and the less restrictive solubility limitation of claim 4. Claim 9 depends directly on claim 1 and creates a separate 18-to-24-hour duration limitation. How broad is the patent’s practical scope?The practical scope is narrower than the commercial category of nicotine patches but potentially meaningful for transparent products. A product would generally need to satisfy all of the following for literal infringement of claim 1:
The independent claim does not require:
This gives the claim flexibility over patch composition and geometry, while the closed backing-material list limits its reach against alternative polymer constructions. What patent landscape surrounds transparent nicotine patches?The relevant patent landscape has several separate layers. Nicotine active-ingredient and transdermal delivery patentsEarly nicotine patch patents generally focused on the concept of delivering nicotine through skin, including reservoir systems, matrix systems, rate control, and treatment of tobacco dependence. Many foundational patents in this field were filed in the 1980s and 1990s and are likely expired or near the end of their statutory terms, depending on priority and patent-term adjustments. These older patents can remain relevant as prior art, but they are less likely to create current blocking rights than later patents directed to formulations, adhesives, manufacturing methods, or specific patch structures. Formulation patentsFormulation patents may cover:
U.S. Patent 8,663,680 does not claim a particular nicotine formulation. A product could therefore face separate formulation patent risks even if it avoids the claimed backing structure. Method-of-use patentsMethod-of-use patents may claim nicotine patches for:
The supplied claims are device claims, not method-of-use claims. They do not require a therapeutic indication or a particular treatment regimen. Manufacturing and packaging patentsManufacturing patents can cover:
The patent’s low-permeability limitations may create practical manufacturing relevance, but claim 1 does not expressly claim a manufacturing step. Is U.S. Patent 8,663,680 likely to be listed in the Orange Book?The claims concern a transdermal device rather than a new chemical entity. Nicotine patches are generally associated with over-the-counter smoking-cessation products rather than a conventional prescription NDA product with an Orange Book patent listing. The Orange Book lists patents submitted for approved drug products under applicable FDA listing rules. A device patent may be listed only if it meets the statutory and regulatory requirements for the relevant approved product. The claims supplied do not establish that Patent 8,663,680 was submitted for an NDA product or appears in the Orange Book. Consequently, the patent should not be treated as an Orange Book patent solely because it covers a nicotine patch. An Orange Book listing, if any, would require confirmation from FDA product and patent-listing records. [2] When does the patent lose exclusivity?The patent’s grant date is March 4, 2014. The expiration date cannot be calculated from the claims or grant date alone. For a U.S. utility patent, the ordinary term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and priority claims. [3] A patent granted in 2014 could therefore expire before, on, or after 2030 depending on its filing and priority history. The legally relevant date is the adjusted expiration date recorded in USPTO prosecution and maintenance records, not the issue date. Patent maintenance-fee status also affects enforceability but does not change the ordinary statutory expiration date. What Paragraph IV risks apply to this patent?A Paragraph IV certification is relevant only when a generic applicant files an ANDA referencing an approved drug product for which the patent is listed in the Orange Book. If Patent 8,663,680 is not Orange Book-listed for the referenced nicotine product, it would not ordinarily generate a Paragraph IV certification requirement. If listed, an ANDA applicant could challenge the patent on grounds including:
A design-around could focus on a backing not within the three listed material categories. A second strategy would use a non-reservoir matrix design, although that approach would depend on how “drug reservoir layer” is construed and whether other patent rights apply. What generic and competitive entry scenarios exist?Scenario 1: Same backing architectureA competitor using one of the listed PET/EVA, HDPE/EAA/nylon/EAA, or specified graft-copolymer films would face the highest literal infringement risk if its product also has the claimed reservoir, adhesive, and transparency characteristics. Scenario 2: Alternative polymer backingA backing made from a different polymer, such as a distinct polyurethane, polyolefin, polyester, or fluoropolymer system, could reduce literal infringement risk. The doctrine of equivalents could remain relevant if the alternative performs substantially the same function in substantially the same way with substantially the same result. Scenario 3: Opaque or visibly nontransparent patchAn opaque product could avoid the transparency limitation in claim 1. That design would sacrifice a commercial characteristic targeted by the patent and could still face other nicotine-patch patents. Scenario 4: Different dosage formAn oral nicotine product, inhaled nicotine product, gum, lozenge, or pouch would not practice the claimed transdermal device. A transdermal product without a distinct reservoir layer could also present a non-infringement position. How strong is the patent estate?The patent appears technically focused rather than platform-wide. Its strengths are:
Its weaknesses are:
What patent litigation and settlement issues matter?The supplied claim set does not establish any infringement complaint, Paragraph IV notice, settlement agreement, or final court decision involving Patent 8,663,680. A litigation assessment must distinguish this patent from the broader body of nicotine-patch disputes involving formulation, adhesive, manufacturing, and regulatory issues. For transaction or launch diligence, the principal legal questions are whether the patent remains enforceable, whether it is assigned to the relevant product owner, whether related continuations remain pending or unexpired, and whether a marketed patch practices the specific backing limitations. Key Takeaways
FAQsDoes U.S. Patent 8,663,680 cover all transparent nicotine patches?No. It covers transparent nicotine patches only when the device also satisfies the claimed backing-material, reservoir, and adhesive limitations. Can a nicotine patch avoid the patent by changing only its adhesive?Possibly, but changing the adhesive alone may not avoid claim 1 if the device still has the claimed backing, nicotine reservoir, transparency, and skin-contact function. Does the patent cover nicotine gum, lozenges, inhalers, or oral nicotine pouches?No. The claims are limited to a transdermal administration device. Are permeability and solubility tested on the finished patch or backing material?The claim language assigns permeability and solubility characteristics to the backing. The applicable test methodology would depend on the patent specification, prosecution history, and expert evidence. Does an 18-hour nicotine patch necessarily infringe claim 9?No. Claim 9 requires the other limitations of claim 1 and delivery for a period of 18 to 24 hours. Duration alone is insufficient. References
More… ↓ |
Drugs Protected by US Patent 8,663,680
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,663,680
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 447398 | ⤷ Start Trial | |||
| Australia | 3121700 | ⤷ Start Trial | |||
| Australia | 774594 | ⤷ Start Trial | |||
| Brazil | 9916214 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
